Komori
Nippon Shinyaku (4516) · InitiativeFirst stated

Nucleic acid drug research partnership with Mina Therapeutics

First written in FY2025. . Latest entry: FY2025.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Nucleic acid medicine research collaboration with Mina Therapeutics for central nervous system diseasesA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025First statedAnnual report

    「A research partnership agreement aimed at creating nucleic acid drugs with potential applications in intractable and rare diseases in the central nervous system field, including an option to obtain an exclusive license to research and develop drug candidates arising from the partnership」

    In April 2024, we entered into a research partnership agreement with Mina Therapeutics aimed at creating nucleic acid drugs for intractable and rare diseases in the central nervous system field. The agreement also includes an option to obtain exclusive research and development rights for drug candidates.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Nippon Shinyaku's next results are scheduled for 2026-11-13. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.